Abstracts tagged "polymyalgia rheumatica"

Abstract Number: 816 • 2018 ACR/ARHP Annual Meeting
Development of Thoracic Aortic Aneurysms in Patients with Polymyalgia Rheumatica: Underdiagnosed Giant Cell Arteritis?
Nicolas Martin Marin Zucaro¹, Marina Scolnik², Florencia Beatriz Mollerach³, Valeria Scaglioni², Luciano Fernando Lo Giudice¹, Jose Maximiliano Martinez P⁴, John Fredy Jaramillo Gallego¹ and Enrique R Soriano⁵, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ²Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ³Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Rheumatology, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina
Background/Purpose: Polymyalgia Rheumatica (PMR) and Giant Cell Arteritis (GCA) are close-related entities. Imaging studies have suggested that subclinical inflammation of the large arteries is frequent…
Abstract Number: 2286 • 2018 ACR/ARHP Annual Meeting
Myositis and Fasciitis By Magnetic Resonance Imaging in Recent-Onset Polymyalgia Rheumatica and Effect of Tocilizumab Therapy
Jean Patrick Laporte¹, Florent Garrigues², Anais Huwart², Sandrine Jousse-Joulin³, Thierry Marhadour¹, Dewi Guellec³, Divi Cornec⁴, Valérie Devauchelle-Pensec³ and Alain Saraux³, ¹CHU Brest, Brest, France, ²Radiology, CHU Brest, Brest, France, ³Rheumatology, CHU Brest, Brest, France, ⁴Rheumatology and UMR1227, Lymphocytes B et Autoimmunité, CHU Brest, Brest, France
Background/Purpose: To assess the prevalence of myofascial inflammatory lesions visible by magnetic resonance imaging (MRI) and their changes after tocilizumab therapy in active polymyalgia rheumatica…
Abstract Number: 2749 • 2018 ACR/ARHP Annual Meeting
Clinical and Anatomical Correlation in Patients with Polymyalgia Rheumatica By 18F-FDG PET/TC. Study of 75 Patients from a Single Referral Center
Diana Prieto Peña¹, Monica Calderón Goercke¹, Javier Loricera², Isabel Martínez-Rodríguez³, Ignacio Banzo³, José Luis Martín-Varillas⁴, Belén Atienza-Mateo⁴, Vanesa Calvo-Río¹, Carmen Gonzalez Vela⁵, Miguel Angel González-Gay² and Ricardo Blanco⁴, ¹Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Nuclear Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁵Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory disease characterized by pain and stiffness of the neck, shoulder and pelvic girdles. It can also be accompanied…
Abstract Number: 792 • 2017 ACR/ARHP Annual Meeting
Glucocorticoid Use and Adverse Events in Patients with Polymyalgia Rheumatica in a Contemporary Population-Based Cohort
Izzat Shbeeb¹, Divya Challa¹, Shafay Raheel², Cynthia S. Crowson³ and Eric L. Matteson⁴, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: To investigate the use of glucocorticoids (GC) and related adverse events (AE) in a long-term, geographically-defined cohort of patients with polymyalgia rheumatica (PMR). Methods:…
Abstract Number: 818 • 2017 ACR/ARHP Annual Meeting
Correlation between the Routine Assessment of Patient Index Data (RAPID3) and Inflammatory Markers in Patients with PMR
Tiffany Kolniak¹, Joshua Baker², Abhijeet Danve³ and Shiv Tej Sehra⁴, ¹Internal Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Yale University, New Haven, CT, ⁴Rheumatology, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA
Background/Purpose: The routine assessment of patient index data (RAPID3) was developed for monitoring and prognosis of patients with Rheumatoid Arthritis and has since been extended…
Abstract Number: 2043 • 2017 ACR/ARHP Annual Meeting
Adherence to American College of Rheumatology Guidelines for Prevention of Glucocorticoid-Induced Osteoporosis in Patients with Polymyalgia Rheumatica
Brittany Frankel¹, Angela Christensen² and Monica Guma³, ¹Internal Medicine, University of California, San Diego, San Diego, CA, ²Rheumatology, University of California, San Diego, San Diego, CA, ³University of California, San Diego, San Diego, CA
Background/Purpose: American College of Rheumatology (ACR) 2010 guidelines recommend that any patient initiating glucocorticoid therapy with an anticipated duration of ≥3 months should receive a…
Abstract Number: 3190 • 2016 ACR/ARHP Annual Meeting
Epidemiology of Polymyalgia Rheumatica 2000-2014: A Population Based Study
Shafay Raheel¹, Cynthia S. Crowson² and Eric L. Matteson¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: To determine time trends in the incidence and survival analysis of polymyalgia rheumatica (PMR) over a 15 year period in a geographically defined population…
Abstract Number: 1340 • 2015 ACR/ARHP Annual Meeting
Value of 18F-FDG PET for Therapeutic Assessment in Patients with Polymyalgia Rheumatica Treated in First Line By Tocilizumab
Xavier Palard¹, Solene Querellou², Maelenn Gouillou³, Alain Saraux^4,5, Thierry Marhadour⁶, Florent Garrigues⁷, Ronan Abgral⁸, Pierre-Yves Salaun⁸ and Valerie Devauchelle^9,10, ¹Department of nuclear medicine, University hospital of Brest, Brest, France, ²Department of nuclear medicine, Université Européenne de Bretagne; Université de Brest; EA3878 (GETBO) IFR148, Brest, French Polynesia, ³Clinical Investigation Centre (CIC) 1412, CHU Cavale Blanche- Institut National de la Santé et de la Recherche Médicale (INSERM), Brest, France, ⁴Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ⁵Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ⁶CHU La Cavale Blanche, Brest, France, ⁷Radiology department, Cavale Blanche Hospital and Brest Occidentale University, Brest, France, ⁸Department of nuclear medicine, Université Européenne de Bretagne; Université de Brest; EA3878 (GETBO) IFR148, Brest, France, ⁹Service de Rhumatologie, CHU Brest, Brest, France, ¹⁰Rheumatology, Brest university medical school, EA 2216, UBO and CHU de la Cavale Blanche,, Brest, France
Background/Purpose: To evaluate the interest of 18F-FDG positron emission tomography-computed tomography (PET-CT) for therapeutic assessment in polymyalgia rheumatica (PMR) patients undergoing tocilizumab (TCZ) therapy at first…
Abstract Number: 1981 • 2015 ACR/ARHP Annual Meeting
Increased Extracellular Water Measured By Bioimpedance Analysis in Polymyalgia Rheumatica Patients – Sign of Volume Overload
Florian Günther^1,2, Boris P. Ehrenstein², Martin Fleck¹ and Rainer Straub¹, ¹Department of Internal Medicine I, University of Regensburg, 93042 Regensburg, Germany, ²Department of Rheumatology/Clinical Immunology, Asklepios Medical Center, 93077 Bad Abbach, Germany
Background/Purpose: Water retention is a typical feature of acute inflammatory episodes, chiefly implemented by the sympathetic nervous system (SNS) and the hypothalamic-pituitary-adrenal (HPA) axis. This…
Abstract Number: 1982 • 2015 ACR/ARHP Annual Meeting
Sonographic Scoring of the Synovial Components in the Shoulder Revealed That Shoulder Synovitis in PMR Patients Is Milder Than That in Elderly-Onset RA Patients with PMR-like Onset
Takeshi Suzuki, Division of Allergy and Rheumatology, Japanese Red Cross Medical Center, Tokyo, Japan; Division of Rheumatology, Mitsui Memorial Hosipital, Tokyo, Japan
Background/Purpose: Through the clinical experience, we noted that there seems to be differences not in the kind or the frequency but in the severity of…
Abstract Number: 1983 • 2015 ACR/ARHP Annual Meeting
Interspinous Bursitis Evaluation By Ultrasound Is Very Useful for Diagnosis of Polymyalgia Rheumatica
Kensuke Kume¹, Kanzo Amano², Susumu Yamada¹, Toshikatsu Kanazawa³, Hiroshi Komori¹, Kazuhiko Hatta⁴ and Noriko Kuwaba⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²rheumatology., hiroshima clinic, Hiroshima, Japan, ³rheumatology, hiroshima clinic, hiroshima, Japan, ⁴Rheumatology, Hatta Clinic, Kure, Japan, ⁵Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Polymyalgia rheumatica (PMR) is a common inflammatory disease of the elderly, and 2012 provisional classification criteria were suggested, however it is provisional and not…
Abstract Number: 1987 • 2015 ACR/ARHP Annual Meeting
Dramatic Efficacy of Tocilizumab As First Line Therapy in Patients with Recent Polymyalgia Rheumatica (PMR): Results of the First Longitudinal Prospective Study
Valerie Devauchelle¹, Alain Saraux², Jean-Marie Berthelot³, Divi Cornec⁴, Yves Renaudineau⁵, Sandrine Jousse-Joulin¹, Thierry Marhadour⁶, Solene Querellou⁷, Florent Garrigues⁸, Michel De Bandt⁹ and Maelenn Gouillou¹⁰, ¹Rheumatology, Brest university medical school, EA 2216, UBO and CHU de la Cavale Blanche,, Brest, France, ²Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ³Rheumatology, University Hospital, Nantes, France, ⁴Department of rheumatology, Brest Occidentale University, Brest, France, ⁵Immunology, Brest University Medical School Hospital, Brest, France, ⁶CHU La Cavale Blanche, Brest, France, ⁷Nuclear Medicine Department, Morvan University Hospital, Brest, France, ⁸Radiology department, Cavale Blanche Hospital and Brest Occidentale University, Brest, France, ⁹Rheumatology department, CHU Fort de France, Fort de France, France, ¹⁰Clinical Investigation Centre (CIC) 1412, CHU Cavale Blanche- Institut National de la Santé et de la Recherche Médicale (INSERM), Brest, France
Background/Purpose: Glucocorticoids (GCs) are the cornerstone treatment of polymyalgia rheumatica (PMR) but induce several adverse events. Methods: Objectives: To evaluate efficacy and safety of tocilizumab…
Abstract Number: 60 • 2014 ACR/ARHP Annual Meeting
Epidemiology of Polymyalgia Rheumatica in Korea
In young Kim¹, Seulkee Lee¹, Hemin Jeong¹, Hyungjin Kim¹, Jiwon Hwang¹, Jaejoon Lee², Eun-mi Koh¹ and Hoon-Suk Cha¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Division of Rheumatology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose Polymyalgia rheumatica (PMR) is a chronic inflammatory disease affecting people older than 50 years. Diagnosis is made based on clinical features and the current…
Abstract Number: 2350 • 2012 ACR/ARHP Annual Meeting
Similarities Exceeds Differences in the Pattern of Joint and Vascular Positron Emission/Computed Tomography Uptake in Polymyalgia Rheumatica and Giant Cell Arteritis
Dario Camellino¹, Silvia Morbelli², Francesco Paparo³, Michela Massollo², Gianmario Sambuceti⁴ and Marco A. Cimmino⁵, ¹Dipartimento Medicina Interna, Clinica Reumatologica, Genova, Italy, ²Dipartimento Medicina Interna, Medicina Nucleare, Genova, Italy, ³Radiology Unit, E.O. Ospedali Galliera, Genoa, Italy, ⁴Dipartimento di Medicina Interna, Medicina Nucleare, Genova, Italy, ⁵Department of Internal Medicine, Academic Unit of Clinical Rheumatology, University of Genova, Genova, Italy
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are two frequent overlapping diseases. The purpose of this work is to examine the relationship between…
Abstract Number: 2360 • 2012 ACR/ARHP Annual Meeting
Prevalence, Management and Outcomes of PET Positive Large Vessel Vasculitis in Difficult to Treat PMR and GCA Patients
Pravin Patil¹, Shaifali Jain², Katerina Achilleos³, Tochukwu Adizie¹, Mark Williams¹, Matthew Tam² and Bhaskar Dasgupta⁴, ¹Rheumatology, Southend University Hospital, Westcliff on sea, United Kingdom, ²Radiology, Southend University Hospital, Westcliff on sea, United Kingdom, ³Rheumatology, Southend University Hospital, Westcliff-on-sea, United Kingdom, ⁴Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom
Background/Purpose: Management of PMR and GCA can be challenging in patients with persistently elevated inflammatory markers, prominent constitutional symptoms and inadequate steroid response. We undertook…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].